CAS Number1048973-47-2
Synonyms1,2,4-Triazine-6-carboxaldehyde,2,3,4,5-tetrahydro-3,5-dioxo; O-benzylfluorescein benzyl ester; dibenzylfluorescein; O,O'-Dibenzylfluorescein; MDA-19; N'-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide; Benzoic acid, 2-[(3Z)-1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene]hydrazide; MDA 19
Molecular FormulaC21H23N3O2
Molecular Weight349.426
Density1.2±0.1 g/cm3
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 1048973-47-2 |
| Catalog No. | 2A-3186218 |
| Chinese Name | MDA 19 |
| Synonyms | 1,2,4-Triazine-6-carboxaldehyde,2,3,4,5-tetrahydro-3,5-dioxo; O-benzylfluorescein benzyl ester; dibenzylfluorescein; O,O'-Dibenzylfluorescein; MDA-19; N'-[(3Z)-1-Hexyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide; Benzoic acid, 2-[(3Z)-1-hexyl-1,2-dihydro-2-oxo-3H-indol-3-ylidene]hydrazide; MDA 19 |
| Molecular Formula | C21H23N3O2 |
| Molecular Weight | 349.426 |
| Density | 1.2±0.1 g/cm3 |
| Storage Condition | 2-8℃ |
| Application | MDA 19 is a human CB2 receptor agonist with a Ki of 43.3 nM. |
| HTC | 2933790090 |
| PubChem ID | 56385432 |
| SMILES | CCCCCCn1c(O)c(N=NC(=O)c2ccccc2)c2ccccc21 |
| InChI | InChI=1S/C21H23N3O2/c1-2-3-4-10-15-24-18-14-9-8-13-17(18)19(21(24)26)22-23-20(25)16-11-6-5-7-12-16/h5-9,11-14,26H,2-4,10,15H2,1H3 |
| InChI Key | ICNRTDOKKSWDRL-UHFFFAOYSA-N |
| Use of | MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. Properties Name N'-(1-Hexyl-2-oxoindolin-3-ylidene)benzohydrazide Synonym More Synonyms MDA-19 Biological Activity Description MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM. IC50 Value: 43.3 nM(Ki)Target: CB2 receptorin vitro: MDA19 displayed 4-fold-higher affinity at the human CB(2) than at the human CB1 receptor (K(i) = 43.3 ± 10.3 vs 162.4 ± 7.6 nM) and nearly 70-fold-higher affinity at the rat CB2 than at the rat CB1 receptor (K(i) = 16.3 ± 2.1 vs 1130 ± 574 nM). In guanosine triphosphate (GTP)gamma[(35)S] functional assays, MDA19 behaved as an agonist at the human CB1 and CB2 receptors and at the rat CB1 receptor but as an inverse agonist at the rat CB2 receptor. In 3',5'-cyclic adenosine monophosphate (cAMP) assays, MDA19 behaved as an agonist at the rat CB1 receptor and exhibited no functional activity at the rat CB(2) receptor. In extracellular signal-regulated kinases 1 and 2 activation assays, in vivo: MDA19 behaved as an agonist at the rat CB2 receptor. MDA19 attenuated tactile allodynia produced by spinal nerve ligation or paclitaxel in a dose-related manner in rats and CB2(+/+) mice but not in CB2(-/-) mice, indicating that CB2 receptors mediated the effects of MDA19. MDA19 did not affect rat locomotor activity. Related Catalog Signaling Pathways >> GPCR/G Protein >> Cannabinoid Receptor Research Areas >> Neurological Disease References [1]. Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemi [2]. Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109. Chemical & Physical Properties Molecular Formula C21H23N3O2 Exact Mass 349.179016 PSA 61.77000 Index of Refraction 1.607 InChIKey ICNRTDOKKSWDRL-UHFFFAOYSA-N Storage condition 2-8℃ Safety Information HS Code 2933790090 Synthetic Route Total: 1 Page N-(n-hexyl)indo... CAS#:56932-61-7 Benzohydrazide CAS#:613-94-5 CAS#:1048973-47-2 Precursor & DownStream Precursor 2 CAS#:56932-61-7 N-(n-hexyl)indo... CAS#:613-94-5 Benzohydrazide DownStream 0 |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 9.0% Ordinary tariff: 20.0% |
| Transport Info | Product name: Summary 2933790090. other lactams. VAT:17.0%. Tax rebate rate:9.0%. . MFN tariff:9.0%. General tariff:20.0% |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| 1H-Imidazol-4-ylmethylamine dihydrochloride | 72631-80-2 | 2A-3186207 |
| KN-62 | 127191-97-3 | 2A-3186211 |
| L-694,247 | 137403-12-4 | 2A-3186214 |
| GW 3965 HYDROCHLORIDE | 405911-17-3 | 2A-3186216 |
| RS 102895 | 300815-41-2 | 2A-3186217 |
| PD158780 | 171179-06-9 | 2A-3186219 |
| 3,3'-Dibromobenzophenone | 25032-74-0 | 2A-3186222 |
| METHOXY-BIS(DIMETHYLAMINO)METHANE | 1186-70-5 | 2A-1186199 |
| PICOLINIC-D4 ACID | 284487-61-2 | 2A-1186224 |
| Diphenyldiazomethane | 883-40-9 | 2A-1186225 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS